scholarly journals HLA and outcome in living donor liver transplantation in primary biliary cirrhosis: A new piece in the jigsaw?

2006 ◽  
Vol 13 (1) ◽  
pp. 8-13 ◽  
Author(s):  
Ye Htun Oo ◽  
James Neuberger
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Biliary Cirrhosis ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Switching From Tacrolimus to Cyclosporine A to Prevent Primary Biliary Cirrhosis Recurrence After Living-Donor Liver Transplantation

10.9738/cc188 ◽  
2013 ◽  
Vol 98 (2) ◽  
pp. 156-159 ◽  
Author(s):  
Hiroaki Shiba ◽  
Shigeki Wakiyama ◽  
Yasuro Futagawa ◽  
Takeshi Gocho ◽  
Ryusuke Ito ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Cyclosporine A ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Immunosuppressive Agents ◽  
Biliary Cirrhosis ◽  
Protective Effects ◽  
Donor Liver ◽  
Donor Liver Transplantation

Abstract Recurrence of primary biliary cirrhosis (PBC) after liver transplantation has been shown to negatively affect graft and patient survival. Recently, protective effects of cyclosporine A against PBC recurrence after liver transplantation have been reported. Participants were 4 patients who underwent living-donor liver transplantation (LDLT) for end-stage liver disease due to PBC. Tacrolimus was used for initial immunosuppression, and this was switched to cyclosporine A at least 3 months after liver transplantation. Targeted trough level of cyclosporine A was 20 times that of tacrolimus. We assessed liver and renal function, as well as antimitochondrial M2 antibody for recipients prior to LDLT, as well as before and after switching immunosuppressive agents. Patients were 1 man and 3 women, and they were ages 45 to 47 years at LDLT. Timing of switching from tacrolimus to cyclosporine A was 13, 3, 7, and 4 months respectively after liver transplantation, and all 4 patients have been on cyclosporine A without adverse effects at 20 to 46 months after transplantation. In 2 of 4 patients who had high titers of antimitochondrial M2 antibody before transplantation, antibody titer did not elevate after LDLT. In the other 2 patients without elevation of antimitochondrial M2 antibody, the titer did not turn positive. Switching from tacrolimus to cyclosporine A was possible without medical problems, and all patients exhibit no recurrence of PBC. Cyclosporine A may be useful for prevention of PBC recurrence after LDLT.

scholarly journals Long-term outcome of living donor liver transplantation for primary biliary cirrhosis

2011 ◽  
Vol 25 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Junichi Kaneko ◽  
Yasuhiko Sugawara ◽  
Sumihito Tamura ◽  
Taku Aoki ◽  
Kiyoshi Hasegawa ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Biliary Cirrhosis ◽  
Donor Liver ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Donor Liver Transplantation

Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis

2007 ◽  
Vol 37 (s3) ◽  
pp. S455-S461 ◽  
Author(s):  
Etsuko Hashimoto ◽  
Makiko Taniai ◽  
Satoru Yatsuji ◽  
Katsutoshi Tokushige ◽  
Keiko Shiratori ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Clinical Outcome ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Biliary Cirrhosis ◽  
Donor Liver ◽  
Donor Liver Transplantation
Sign in / Sign up

Export Citation Format

Share Document